Read our Recent Headlines

October 13 Biotech Update

More of the same with winners drifting higher in the sector and losers drifting lower. I had hoped that volume and interest would have picked up this week but it.

October 12 Biotech Update

Volume continues to be anemic but perhaps it will start to pick up into a series of conferences (world lung and SITC) and earnings. I say perhaps but it would.

October 11 Biotech Update

More of the same. The sector seems to be content to drift on low volume, which is pretty consistent with the broader market and the lack of fundamental news. Odds.

October 10 Biotech Update

I was in my office yesterday to write but there is really nothing happening in the sector that is exceptionally newsworthy. I was hoping we would have some news today.

October 6 Biotech Update

News continues to be a little slow but there are some companies that I want to follow up on given some discussions that have been percolating. In general, the sector.

October 4 Biotech Update

We got some news to talk about today and it just so happens to be some good news and some bad news. In both cases, the news is specific enough.

October 2 Biotech Update

There is not a lot of sector specific news to start the week, although there seems to be some minor news. In these situations the sector tends to follow the.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!